Clinical Trial

RECOMMEND Platform Trial

Study acronym: RECOMMEND
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this platform trial is to determine the efficacy, safety and cost-effectiveness of various interventions in patients with acute cardiorespiratory failure requiring extracorporeal membrane oxygenation (ECMO) The main question the platform trial aims to address is to determine the effect of a range of interventions on survival, organ support and resource utilisation to day 28 for hospitalised patients receiving ECMO. Researchers will compare various interventions within multiple platform trial domains to see if the interventions have effects on survival, organ support and resource utilisation for the patient cohort. Participants will be enrolled in accordance with the platform trial's domain structure to answer the research questions.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-25; most recent amendment 2026-05-11.
Status change: Not Yet Recruiting → Recruiting 2026-05-11
Trial Details
NCT Number NCT06526533
Lead Sponsor Australian and New Zealand Intensive Care Research Centre
Collaborators: Monash University, Berry Consultants, Research Path
Conditions Extracorporeal Membrane Oxygenation Complication, ARDS (Acute Respiratory Distress Syndrome), Intensive Care Medicine, Cardiac Arrest (CA), Critical Illness
Enrollment 600 participants
Start Date 2026-03-23
Primary Completion 2028-06 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-13